Trial
A Clinical Study to Assess Safety, Efficacy and Pharmacodynamic Profile of GNT0004 in Duchenne Muscular Dystrophy
GNT0004 is a one-time gene therapy delivering a functional dystrophin gene to slow Duchenne muscular dystrophy progression.
No directly tagged education is live for Gastroenterology yet. Use the specialty context below plus relevant cross-specialty education while the dedicated hub is expanded.
Use the specialty context and cross-specialty learning below while dedicated modules, podcasts and webinars are added.
GNT0004 is a one-time gene therapy delivering a functional dystrophin gene to slow Duchenne muscular dystrophy progression.
MAS825 tested as treatment for rare genetic inflammatory disorders caused by NLRC4, XIAP, or CDC42 mutations.
Trial testing linvoseltamab alone or with carfilzomib versus standard treatments in patients with relapsed/refractory myeloma after 1-3 prior therapies.
Elafibranor versus placebo for primary sclerosing cholangitis: a trial assessing efficacy and safety in 350 adults over five years.
recorded webinar focused on SGLT2 Inhibitors in diabetes and metabolic medicine. Use the recording with the slide outline to review mechanism, evidence,…
Recorded webinar focused on JAK inhibitors in rheumatology and immune-mediated inflammatory disease. Reviews JAK-STAT signalling, patient selection, ORAL Surveillance safety signals, cardiovascular…
recorded webinar focused on GLP-1 Agonists in diabetes and metabolic medicine. Use the recording with the slide outline to review mechanism, evidence,…